Ameriprise
RXRX icon

Ameriprise’s Recursion Pharmaceuticals RXRX Stock Holding History

Ameriprise’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$114K Sell
37,139
-5,745
-13% -$22.2K ﹤0.01% 3948
2025
Q4 		$175K Sell
42,884
-2,987
-7% -$14.8K ﹤0.01% 3949
2025
Q3 		$224K Sell
45,871
-4,143
-8% -$21.8K ﹤0.01% 3880
2025
Q2 		$253K Sell
50,014
-43,925
-47% -$216K ﹤0.01% 3756
2025
Q1 		$497K Buy
93,939
+2,269
+2% +$16.5K ﹤0.01% 3486
2024
Q4 		$620K Buy
91,670
+29,034
+46% +$195K ﹤0.01% 3441
2024
Q3 		$413K Sell
62,636
-6,497
-9% -$46.6K ﹤0.01% 3552
2024
Q2 		$518K Sell
69,133
-11,481
-14% -$100K ﹤0.01% 3403
2024
Q1 		$804K Buy
80,614
+40,103
+99% +$447K ﹤0.01% 3259
2023
Q4 		$399K Buy
+40,511
New +$289K ﹤0.01% 3529

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ameriprise's RXRX Position: Q1 2026 in Review

Ameriprise reduced its Recursion Pharmaceuticals (RXRX) stake by 13% in Q1 2026, selling an estimated $22.2K and leaving 37,139 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #3948.

Ameriprise first reported a position in RXRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $804K in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Ameriprise held 37,139 shares of Recursion Pharmaceuticals worth $114K as of Q1 2026.
  • Ameriprise sold 5,745 Recursion Pharmaceuticals shares in Q1 2026, an estimated $22.2K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3948 holding.
  • Ameriprise first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Ameriprise's Recursion Pharmaceuticals position peaked at $804K in Q1 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.